



2023 Bloom Burton
Award Gala

September 28, 2023

PROGRAM

Four Seasons Hotel Toronto



Content

2	Welcome from Bloom Burton & Co.
3	Agenda
4	Welcome from Pieter Cullis
6	Message from the Prime Minister
8	Message from the Premier of Ontario
10	Message from the Mayor of Toronto
13	Finalists
23	Judges
28	Table Sponsors




Welcome



We are honoured to be hosting the 2023 Bloom Burton Award Gala at the Four Seasons Hotel Toronto on September 28, 2023, to spotlight and celebrate the exceptional finalists for the 2023 Bloom Burton Award.

Each year, the Bloom Burton Award celebrates those people who demonstrate excellence in the healthcare field and is given to an individual in any role, from any field of healthcare, and at any stage of development for their amazing and impactful work in the immediately preceding year. We aim to recognize and celebrate those who advance medical science, attract or provide risk capital, launch new products or companies, or change policy with a dramatic and positive impact on the world stage.

For 2023, we received nominations from the public at large and our international and esteemed judging panel narrowed down the list to the following outstanding finalists, in alphabetical order:



Stephen Dilly, Formerly Sierra Oncology
Ian Mortimer, Xenon Pharmaceuticals
Dave Wessinger and Mike Wessinger, PointClickCare

We hope, in learning more about these finalists, that you will be inspired by them as they take the Canadian healthcare industry to new heights. We are incredibly honoured to share and celebrate each of their stories with you tonight.

Please raise a glass and toast their achievements with us.

Cheers!

Brian & Jolyon



Agenda

**6:00
PM**

Cocktail Reception

**7:00
PM**

**Bloom Burton Award Program
and Dinner**

Welcome remarks from
Brian Bloom and Jolyon Burton

Celebrating Stephen Dilly

Celebrating Ian Mortimer

Celebrating Dave Wessinger and
Mike Wessinger

Remarks and Winner
Announcement by Pieter Cullis

**10:00
PM**

Networking and Entertainment



Message from Pieter Cullis

2022 Bloom Burton Award Winner

#BBAward2023

Dear Colleagues

Welcome to the 2023 Bloom Burton Award Gala! This is an evening where we celebrate Canadian excellence in innovation in the life science sector. It is no easy task to be internationally successful in the highly competitive fields of developing new therapeutics and healthcare data analytics, but tonight's finalists have done just that. Their success demonstrates that Canada has the infrastructure, the people and the brainpower to achieve greatness and serves as an inspiration to scientists and entrepreneurs across Canada.

I am sure that the 2023 Bloom Burton Award finalists can tell stories of being faced with seemingly insurmountable obstacles and working their way through them to achieve success. They have likely received convincing advice to change direction when the chips are down but have carried on regardless. They are a remarkably determined group and a lesson to us all, we look forward to the stories they will tell tonight.

We have to give thanks to Bloom Burton & Co. (particularly Brian and Jolyon) for making this event possible. It is a landmark on the Canadian scene. They have established a rigorous nomination process, assembled a remarkable team of judges and organized an event that is an amazing celebration.

I cannot overemphasize the importance of the life science industry to Canada's future. Medicine is at a tipping point and will change enormously over the coming years.

I cannot overemphasize the importance of the life science industry to Canada's future. Medicine is at a tipping point and will change enormously over the coming years. Forces at work include the move to personalized, preventive healthcare rather than reactive "sick-care", the growing possibility of targeted "precision" medicines and the implementation of data-driven, evidence-based healthcare. Now is the time for us to invest heavily in these opportunities.

In order to realize these opportunities some changes are going to be necessary. We need to make our institutions, particularly universities, more entrepreneurial. The medical system itself must become less fragmented and more receptive to innovation, particularly in the fields of information technology and utilization of patient data. And we need the examples, such as the people we honour tonight, to motivate young entrepreneurs to grow a tradition of life science innovation so that we take advantage of discoveries made here in Canada.

The global life science industry (pharmaceutical, biotech, and medtech) is nearly \$3 trillion and is growing. Canada needs to be a major player in a sector that will become increasingly dominant in the years to come. As tonight's finalists demonstrate, we have the talent and the drive to do this. Let's celebrate their success and let it inspire us to achieve more!

Sincerely,

Pieter R. Cullis, PhD, FRSC, OC
Ex-Scientific Director & CEO, NanoMedicines Innovation Network
Canada's National Centre of Excellence in Nanomedicines
Professor, Department of Biochemistry and Molecular Biology
University of British Columbia



*Prime Minister of
Canada*



#BBAward2023





PRIME MINISTER • PREMIER MINISTRE

Message from the Prime Minister of Canada

It is with great pleasure that I welcome everyone to the 2023 Bloom Burton Award Gala.

Events such as this give us all the opportunity to recognize and appreciate the knowledge, expertise, and innovation Canadians have to offer.

I would like to wish all the finalists congratulations. You are here today not only as a recognition of your hard work, but also as an acknowledgment of the advancements you have made in your field for our country.

I would like to take this moment to thank the entire team behind the Bloom Burton Award Gala for organizing an event that highlights Canada's biotechnology and pharmaceutical sectors. Canadians have made significant contributions to these fields, and events, such as this Gala, are needed to celebrate Canadian innovation and inspire others.

With my warmest regards and very best wishes.

Ottawa
2023

*Premier of the
Province of
Ontario*



#BBAward2023





Premier of Ontario - Premier ministre de l'Ontario

September 28, 2023

A MESSAGE FROM PREMIER DOUG FORD

Warm greetings and welcome to everyone taking part in the 2023 Bloom Burton Award Gala. Tonight, you gather to recognize the scientists, inventors, executives, entrepreneurs, policy makers and leaders who made the greatest contributions to Canada's health care sector in the past year.

Congratulations to this year's finalists: Stephen Dilly of Sierra Oncology, Ian Mortimer of Xenon Pharmaceuticals, and Dave and Mike Wessinger of PointClickCare. We have some of the best minds working in our health care industry, and your achievements are proof of that.

A big thank you to the team at Bloom Burton & Co. for organizing this event. Your commitment to celebrating excellence in the Canadian health care sector helps build a culture that rewards the pursuit of knowledge and innovation.

As you know, Ontario's life sciences ecosystem supports thousands of good-paying, high-skilled jobs in communities across our province. Our government will continue working to unlock the full potential of the sector, support innovation and new technologies, and enhance companies' competitiveness at home and on the global stage.

Have a memorable gala.

A handwritten signature in black ink, appearing to read "Doug Ford".

Doug Ford
Premier

Mayor of Toronto



CITY OF
TORONTO

Message from the Mayor

I would like to warmly welcome everyone attending the 2023 Bloom Burton Award Gala.

Congratulations to this year's Bloom Burton Award recipients, who are being recognized for their significant contributions to Canada's innovative healthcare industry. With nominees from a wide range of health and research-related industries, I am confident that Canada's future in medical care and treatment development is in good hands. Your contributions to Canada's health care industry will help pave the way for future innovation.


The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities. Your tremendous efforts and talents impact the lives of many and improve the overall health of our residents.

On behalf of Toronto City Council, please accept my best wishes for a memorable event.

Yours truly,

Olivia Chow
Mayor of Toronto

OFFICE OF THE MAYOR
100 QUEEN STREET WEST, TORONTO, ONTARIO, M5H 2N2





2024

BLOOM BURTON & CO.
HEALTHCARE INVESTOR
CONFERENCE


April 16 - 17



Finalists

Our three finalists are celebrated for their incredible contributions to the Canadian healthcare sector.

Each of the finalists have received a \$25,000 cash prize, and a single winner will have the honour of being the recipient of the 2023 Bloom Burton Award.



Stephen Dilly

Formerly
Sierra Oncology



Ian Mortimer

Xenon Pharmaceuticals



Dave Wessinger


PointClickCare



Mike Wessinger

PointClickCare

Stephen Dilly



#BBAward2023





STEPHEN DILLY

Former President and Chief Executive Officer Sierra Oncology

Stephen Dilly is currently CEO of Codexis Inc. During a 35-year industry career, he has been associated with the development, approval and launch of more than 20 novel medications across multiple therapeutic areas.

Stephen was CEO of Sierra Oncology from May 2020 until August 2022. During his tenure, Sierra Oncology successfully executed the Phase 3 MOMENTUM trial in myelofibrosis patients with anemia in 160 centers across 16 countries in Europe, North America and Asia despite the challenges of the COVID pandemic. Positive top-line data release in early 2022 was followed by an over-subscribed \$150 million follow-on offering, NDA filing, and then acquisition of the Company by GlaxoSmithKline for \$1.9 billion in July 2022.

Previously, Stephen served as CEO of Aimmune Therapeutics and led the development of Palforzia, the first FDA-approved treatment for peanut allergy. Aimmune Therapeutics was acquired by Nestle Health Science for \$2.6 billion.

Stephen also held executive roles at Genentech, Chiron and SmithKline Beecham.


Stephen believes passionately that the key determinants of success are clarity of purpose and focus. Often the role of the leader is to set a clear direction, challenge the organization to go outside the comfort zone and to remove the distractions. Breakthroughs are almost always the product of teamwork galvanized by a compelling mission.



Jan Mortimer



#BBAward2023





IAN MORTIMER

President and Chief Executive Officer, Xenon Pharmaceuticals


Ian Mortimer has served as President and Chief Executive Officer of Xenon Pharmaceuticals since June 2021, previously joining the company as its Chief Financial Officer in 2013. Prior to Xenon, Ian served as Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (now Arbutus Biopharma Corporation), a Nasdaq-listed biotechnology company, from 2007 until 2013. Ian was responsible for all aspects of Tekmira's finance and capital markets activities and led its listing on Nasdaq in 2010. From 2004 to 2007, Ian was Chief Financial Officer at Inex Pharmaceuticals and held various other positions from 1997 to 2004.

Since July 2020, Ian has served on the board of directors of Perimeter Medical Imaging AI, Inc., a publicly-traded medical device company focused on advanced medical imaging and artificial intelligence tools.


Ian has an M.B.A. from Queen's University, a B.Sc. in Microbiology from the University of British Columbia and is a Chartered Professional Accountant, Certified Management Accountant.



Dave Wessinger



#BBAward2023





DAVE WESSINGER

**Co-Founder and Chief Executive Officer,
PointClickCare**

Dave Wessinger is the Co-Founder and Chief Executive Officer of PointClickCare. For more than 20 years, Dave has worked to transform the senior care technology industry and tackle complex challenges across the healthcare continuum.

In 2000, Dave co-founded PointClickCare with his brother Mike, pioneering healthcare's digital transformation and driving improved outcomes for seniors and care teams through technology. Today, PointClickCare boasts one of Canada's most admired corporate cultures and employs over 2100 employees who serve over 27,000 care providers, establishing PointClickCare as the largest cloud-based healthcare platform in North America.

Dave has earned recognition for the foresight and innovation that helps thousands reimagine the way technology can be used to communicate, collaborate, and improve care across the healthcare continuum. Instrumental in garnering recognition for PointClickCare as one of Deloitte's best-managed companies for eight consecutive years, Dave also aided in earning PointClickCare a spot on Forbes Top Cloud 100 List for two consecutive years.



Mike Wessinger



#BBAward2023





MIKE WESSINGER

**Co-Founder and Executive Chair,
PointClickCare**

Mike Wessinger is PointClickCare’s Co-Founder and Executive Chair of the board. Prior to taking on the role of Executive Chair, Mike served as PointClickCare’s Chief Executive Officer from 1995 to 2021.

Mike’s vision and leadership established PointClickCare as the first cloud-based health information system for the senior care industry. Relentless in his pursuit to disrupt the healthcare status quo, Mike’s forward-thinking vision drove the organization to level silos across the healthcare ecosystem, creating North America’s largest care collaboration network.

In his role as Executive Chair, Mike continues to champion corporate culture, enhance governance, recruit diverse talent, and partner with internal and external boards and teams to solve critical healthcare challenges and propel PointClickCare forward as a world-class organization.

Outside of PointClickCare, Mike serves on the board of RX Food and C100, where he actively leverages his years of experience to coach and mentor leaders at the helm of rapidly scaling tech companies.



The background is a vibrant orange with various festive elements. At the top, there are several snowflakes in blue, green, and pink. Below them are large, semi-transparent circles in orange, green, and red. In the bottom left corner, there is a stylized Christmas tree composed of colorful geometric shapes (blue, green, red, white). In the bottom right, there is a candy cane with red and white stripes and a green snowflake. The text is centered in a bold, white, sans-serif font.

SAVE THE DATE

Bloom Burton & Co.
2023 Holiday Party
November 29, 2023





Judges

Our esteemed panel of judges are respected international leaders in healthcare investment, entrepreneurship and journalism.

Judges

Michael Altman

Managing Director, Perceptive Advisors



Michael Altman joined Perceptive in 2007 and is a Managing Director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III.

Prior to Perceptive, he was a healthcare trader and analyst at First New York Securities.

Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Lyra Therapeutics, Nautilus Biotechnology, and Vitruvius Therapeutics.

Christopher Arendt

**Head, Oncology Cell Therapy and Therapeutic Area Unit,
Takeda**



Based at Takeda's Cambridge, Massachusetts, R&D campus, Christopher Arendt is responsible for oversight of Takeda's global Oncology Development portfolio. Since joining Takeda in 2015, Christopher has helped reshape Takeda's Oncology pipeline with a strong network of global collaborators, emphasizing emerging science leveraging immunological modalities and mechanisms towards curative-intent cancer medicines.

Christopher is a Ph.D. Immunologist who carried out postdoctoral training with Dan Littman at the New York University Medical Center.

Prior to joining Takeda, Christopher spent more than 13 years at Sanofi, where he led global teams advancing novel immunotherapies for cancers and inflammatory diseases.



Karen Bernstein

Co-Founder & Chairman, BioCentury Inc.



Karen Bernstein is Co-Founder and Chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015.

She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. Karen also serves on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the Board of Overseers of Scripps Research.

Karen holds a Ph.D. in Political Science from Stanford University and a B.A. in Politics and History from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council.

Carl Gordon

Managing Partner, OrbiMed Advisors



Carl Gordon is a Managing Partner and Head of Global Private Equity at OrbiMed. Carl was a Senior Biotechnology Analyst at OrbiMed's predecessor firm Mehta and Isaly. Carl was a Fellow at The Rockefeller University from 1993 to 1995.

Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a Bachelor of Arts Degree from Harvard College. He was included on the Forbes Midas List of top venture capital investors in recent years.





Dennis Purcell

Founder & Senior Advisor, Aisling Capital



Dennis Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Dennis is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.



Melinda Richter

Global Head, Johnson & Johnson Innovation – JLABS



Melinda Richter is the champion for entrepreneurs and start-ups who drive potential breakthrough ideas and approaches with the goal of better health for all. She founded Johnson & Johnson Innovation – JLABS, the global incubator network of Johnson & Johnson Innovation, to connect early-stage companies to critical resources, expertise and community to support their success. Melinda co-leads Johnson & Johnson Innovation’s integrated approach to address Diversity, Equity and Inclusion (DEI) in the early stages of a company’s life.

Before joining Johnson & Johnson, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks in Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also raised capital and secured large corporate deals for companies in both the life science and technology space.



Camille Samuels

Partner, Venrock



Camille Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health at Venrock. Temperamentally an early-stage investor and company helper, Camille currently serves on the board of Cavalry, Iris, Mahzi, Ocelot, Unity (UBX), and is a board observer at Interdict. She previously served on the board of several exited Venrock portfolio companies.

Prior to Venrock, Camille was a Managing Director at Versant Ventures. During her early career, Camille worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and she was a management consultant at LEK.

Sponsors

Table Sponsors




#BBAward2023



THANK YOU FOR SUPPORTING OUR ANNUAL CELEBRATION OF CANADIAN HEALTHCARE!

Half Table Sponsors





Celebrating 15 years as Canada's Biggest Healthcare Cheerleader.


Visit our new office in 2024 at:

Bay Wellington Tower
181 Bay St. Suite 3401
Toronto, ON M5J 2T3



bloom burton & co

/accelerating returns in healthcare®



Saturday, September 30, 2023, is National Truth and Reconciliation Day and we would like to acknowledge the land on which the 2023 Bloom Burton Award Gala takes place as the traditional land of the Anishinabewaki, Wendake-Nionwentsio, Haudenosaunee, and the Mississaugas of the Credit.

Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work and host on this land.



#BBAward2023

